| Survived | Died | Overall Survival (OS) | Event Free Survival (EFS) | ||||||
| n | % | n | % | OS | HR (95% CI) | EFS | HR (95% CI) | ||
| Gender | Female | 16 | 80.0 | 4 | 20.0 | 75.0 | 1.05 (0.26 to 4.25) | 67.0 | 1.02 (0.25 to 4.08) |
| Male | 18 | 81.8 | 4 | 18.2 | 71.0 | 66.0 | |||
| Age (yr) | <1 yr | 15 | 93.8 | 1 | 6.3 | 82.0 | 0.18 (0.02 to 1.51) | 75.0 | 0.19 (0.02 to 1.52) |
| ≥1 yr | 19 | 73.1 | 7 | 26.9 | 62.0 | 59.0 | |||
| median (min, max) | 16.0 (0, 91) | 27.5 (8, 65) |
|
|
|
| |||
| Tumor location | Others | 15 | 93.8 | 1 | 6.3 | 89.0 | 0.24 (0.03 to 1.95) | 85.0 | 0.21 (0.02 to 1.68) |
| Adrenal | 19 | 73.1 | 7 | 26.9 | 63.0 | 55.0 | |||
| Diagnosis | Ganglioneuroma | 2 | 100.0 | 0 | 0 | 100.0 |
| 100.0 |
|
| Ganglioneuroblastoma | 4 | 66.7 | 2 | 33.3 | 48.0 |
| 24.0 |
| |
| Neuroblastoma | 28 | 82.4 | 6 | 17.6 | 74.0 | 2.64 (0.51 to 13.67) | 70.0 | 2.45 (0.47 to 12.67) | |
| LDH Grade | <5*Normal | 25 | 89.3 | 3 | 10.7 | 73.0 | 0.26 (0.06 to 1.10) | 73.0 | 0.26 (0.06 to 1.10) |
| >5*Normal | 8 | 61.5 | 5 | 38.5 | 53.0 | 53.0 | |||
| median (min, max) | 480.0 (269, 5963) | 1405.5 (315, 7666) |
|
| |||||
| Urine Catecholeamines | Negative | 10 | 90.9 | 1 | 9.1 | 90.0 |
| 88.0 |
|
| Positive | 19 | 82.6 | 4 | 17.4 | 60.0 | 0.16 (0.02 to 1.59) | 54.0 | 0.13 (0.01 to 1.31) | |
| Not done | 5 | 62.5 | 3 | 37.5 | 48.0 | 0.46 (0.10 to 2.06) | 32.0 | 0.43 (0.10 to 1.94) | |
| Stage (INSS) | Stage 4S, 1 & 2 | 10 | 100.0 | 0 | 0 | 100.0 | 0.03 (0.00 to 20.73) | 100.0 | 0.03 (0.00 to 33.18) |
| Stage 3 & 4 | 24 | 75.0 | 8 | 25.0 | 64.0 | 59.0 | |||
| MYCN Status | Not Amplified | 23 | 88.5 | 3 | 11.5 | 72.0 |
| 62.0 |
|
| Amplified | 7 | 70.0 | 3 | 30.0 | 70.0 | 0.45 (0.07 to 2.69) | 66.0 | 0.46 (0.07 to 2.80) | |
| Not done | 4 | 66.7 | 2 | 33.3 | 64.0 | 1.11 (0.18 to 6.77) | 61.0 | 1.17 (0.19 to 7.10) | |
| Tumor Differentiation | Differentiated | 5 | 71.4 | 2 | 28.6 | 74.0 | 0.64 (0.15 to 2.69) | 74.0 | 0.68 (0.16 to 2.92) |
| Undifferentiated | 9 | 90.0 | 1 | 10.0 | 71.0 | 65.0 | |||
| INPC | Unfavorable Histology | 12 | 85.7 | 2 | 14.3 | 84.0 | 0.63 (0.13 to 3.15) | 81.0 | 0.68 (0.14 to 3.41) |
| Favorable Histology | 20 | 76.9 | 6 | 23.1 | 61.0 | 52.0 | |||
| INSS Risk Assessment | Low Risk | 11 | 100.0 | 0 | 0 | 100.0 |
| 100.0 |
|
| Intermediate Risk | 11 | 100.0 | 0 | 0 | 100.0 | 0.01 (0.00 to 35.04) | 100.0 | 0.01 (0.00 to 66.06) | |
| High Risk | 12 | 60.0 | 8 | 40.0 | 48.0 | 0.01 (0.00 to 55.69) | 44.0 | 0.01 (0.00 to 33.14) | |